Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000658016 | SCV000779787 | pathogenic | not provided | 2023-04-19 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Ambry Genetics | RCV001265754 | SCV001443923 | uncertain significance | Inborn genetic diseases | 2020-03-23 | criteria provided, single submitter | clinical testing | The alteration results in an amino acid change:_x000D_ _x000D_ The c.4387G>A (p.G1463R) alteration is located in coding exon 20 of the MED13L gene. This alteration results from a G to A substitution at nucleotide position 4387, causing the glycine (G) at amino acid position 1463 to be replaced by an arginine (R). The alteration is not observed in population databases: _x000D_ _x000D_ Based on data from the Genome Aggregation Database (gnomAD), the MED13L c.4387G>A alteration was not observed, with coverage at this position. The altered amino acid is conserved throughout evolution:_x000D_ _x000D_ The G1463 amino acid is conserved in available vertebrate species. in silico prediction is inconclusive:_x000D_ _x000D_ The in silico prediction for the G1463R alteration is inconclusive. Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |